In contrast to today's drug therapy for Alzheimer's disease, immunotherapy is directed at the neurotoxic amyloid beta peptide that directly or indirectly leads to cognitive decline in patients with Alzheimer's disease. Here, APP is linked to early-onset autosomal dominant Alzheimer disease.